Application of NK cell infusion in preventing relapse of leukemia after haploidentical Hematopoietic stem cell transplantation

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039892

Enrollment

Unknown

Registered

2020-11-13

Start date

2020-11-01

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute leukemia

Interventions

Treatment Group:Haplo-HSCT + NK cell infusion

Control Group:Haplo-HSCT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Age under 50 years old, sex is not limited; (2) Patients with AML meet the WHO criteria for high-risk AML; (3) There is a relative haploid donor and no donor Hematopoietic stem cell; (4) Women in the non-lactation period, non-pregnancy; (5) No serious liver, heart and kidney dysfunction; (6) Signed informed consent.

Exclusion criteria

Exclusion criteria: (1) A pregnant or nursing woman; (2) Be Over the age of 50 years; (3) Severe major organ dysfunction; (4) Have received immunocytotherapy including dendritic cell, cytokine-induced cells (CIK), cytotoxic lymphocyte or other types of immunocytotherapy; (5) A history of allergic reaction to recombinant human IL-2.

Design outcomes

Primary

Measure	Time frame
MRD;GVHD;OS;	—

Countries

China

Contacts

Public ContactWang Hengxiang

Air Force Special Medical Center (Former Air Force General Hospital)

wanghengxiang123@aliyun.com+86 10-68410099

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026